AIM ImmunoTech Inc.

AIMAMEX • USD
ThemeHealthcare - Oncology›Immunotherapy & Immuno-Oncology
0.26 USD
↘ 0.02 (5.86%)🔴AT CLOSE (AS OF 08:15 PM EDT)
🔴Market: CLOSED

Shares of AIM ImmunoTech Inc. (AIM) are trading at $0.26. The technical outlook is "Sell" and the fundamental picture shows "Neutral". This is driven by a concerning Altman Z-Score in the distress zone, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On the valuation front, AIM trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.

Technical & fundamental data as of Jul 17, 2026.

Open?$0.27
High?$0.27
Low?$0.25
Prev. Close?$0.27
Volume?486.1K
Avg. Volume?7.1M
VWAP?$0.26
Rel. Volume?0.07x
Bid / Ask
Bid?$0.26 × 300
Ask?$0.26 × 4.1K
Spread?$0.00
Midpoint?$0.26
Valuation & Ratios
Market Cap?7.5M
Shares Out?27.7M
Float?7.8M
Float %?96.1%
P/E Ratio?N/A
P/B Ratio?3.52
EPS?-$0.48
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
Themes
Healthcare - Oncology›Immunotherapy & Immuno-OncologyBiotech - Drug Development›Rare Disease TherapeuticsBiotech - Drug Development›Infectious Disease & Vaccines
Employees
21
Market Cap
7.6M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.aimimmuno.com
Listed
1995-11-02
Address
2117 SW HIGHWAY 484
OCALA, FL 32801
Phone: 352-448-7797
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
40
Z-Score?
0
Momentum?
75
Short Sent.?
65
Piotroski F-Score?4/9Mixed
Altman Z-Score?-75.61Distress
Confidence?48%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?28.11%Squeeze Risk
Short Interest?2.2M
Days to Cover?1.0
Free Float7.8M
Avg Daily Volume2.3M
Settlement Date2026-06-30
Financial Health
Current Ratio?1.01Adequate
Quick Ratio?1.01Adequate
Cash Ratio?0.95Adequate
Debt/Equity?1.98High
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
100
S&P
49
3.52FAIR▾
P/S?
Peers
100
S&P
3
79.63HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-0.6CHEAP▾
EV/Sales?
Peers
100
S&P
3
62.59HIGH▾
Returns & Efficiency
ROE?
S&P
3
-624.8%WEAK▾
ROA?
S&P
3
-154.6%WEAK▾
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$5.9M
Fundamentals ratios updated end of day
MarketsMoversWatchlist